Two Members of Congress Just Named What They Want Regulated in Psychedelic Therapy. Credentialing Is on the List
Two members of Congress who co-chair the bipartisan psychedelics caucus have named what they want written into federal law. Representatives Jack Bergman and Lou Correa listed four priorities in The Hill on October 13. Standards for who is qualified to deliver this care is one of them.
Credentialing standards arrive as a cost before they arrive as a rule. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| Who wrote it | Reps. Jack Bergman of Michigan and Lou Correa of California |
| What they run | Co-chairs of the bipartisan Congressional caucus on psychedelic therapies |
| The ask | National standards for service delivery and practitioner credentialing |
| Also named | Labeling requirements for psychedelic medicines |
| Also named | Codified best practices for set and setting, crisis response and integration |
| The timing | They want guidance and verification systems in place before FDA approvals |
Why This Opinion Column Is Worth Reading
Op-eds from advocacy groups are easy to skip. This one is different because of who signed it.
Bergman and Correa co-chair the Congressional Psychedelics Advancing Therapies Caucus, usually shortened to the PATH Caucus. It is the bipartisan group in the House organized around these treatments.
That makes them the two members most likely to draft whatever framework eventually moves.
When caucus co-chairs publish a list of priorities, that list is a preview of legislative text.
We have tracked the pair before, when they pushed FDA to speed up reviews and when Congress moved to turn the executive order into statute.
It is also a signal to anyone building a service line now. Standards set later tend to grandfather whoever already meets them.
What They Are Asking For
National standards for service delivery and practitioner credentialing. This is the item with the most direct operational consequence.
Labeling requirements for psychedelic medicines. A label defines who must be present and for how long, which sets the cost of every session.
Codified best practices. They name set and setting, crisis response and integration support as things that should be written down rather than assumed.
Guidance and verification systems before approval. They want the framework standing before the first product clears FDA, not after.
The Credentialing Item Is the One to Watch
Nobody currently agrees on who is qualified to deliver this care.
We mapped that landscape when MAPS announced a training partnership, and found states, manufacturers, trial protocols and professional bodies all defining the role differently.
A federal credentialing standard would collapse those into one. That is good for operators who want clarity and expensive for operators who guessed wrong.
Clinicians who already hold a license to practice remain the safest foundation. No plausible federal framework discards psychiatrists, nurse practitioners, physician assistants, CRNAs or licensed therapists.
Training on top of an existing license is additive under any of these scenarios. A staff member who completes a recognized program is better prepared whichever way the rules land.
The cost of that training is modest next to the cost of rebuilding a team around a credential nobody anticipated.
The Case They Make
The argument is built on scale. They cite more than 130 Americans dying by suicide each day, including more than 20 veterans.
They point to treatment-resistant depression, PTSD, substance use disorders and anxiety as the targets, and credit the administration for granting Breakthrough Therapy designation to psilocybin and MDMA products.
The PATH Caucus issued a formal request for information two years ago on how to integrate this medicine into the health system. This column reports what came back.
Their summary of those responses is notable for its restraint. Psychedelics are not necessarily magic bullets, they write, but delivered in a safe and structured environment they can be transformative.
That framing matters for how a federal standard would be written. A caucus that calls these treatments transformative but not magic is describing guardrails, not restrictions.
What This Signals for Clinics
Supervised delivery is the model being legislated toward. Every item on their list assumes a structured setting with a trained practitioner present.
Documentation is going to be the currency. Verification systems mean somebody checks, and the clinics that can show their protocols will clear that bar first.
Existing certification is a head start. A site already running REMS monitoring has most of the operational pattern in place, which is part of why the first psilocybin clinics will probably be Spravato clinics.
Clinics tracking what is already on the calendar can use our list of 6 regulatory deadlines.
Not Law, But the Clearest Signal Yet
This is not law. It is an opinion column, and it binds nobody.
It is also the clearest public statement yet of what the two members most likely to write the bill actually want in it.
Their priorities line up with what FDA spent its September hearing on, where the real fight was over the label. The direction of travel is consistent.
Patients looking for supervised care can start with our directory of verified clinics.
This article is for informational purposes and is not legal advice. Psilocybin and MDMA assisted therapies are not approved by the FDA.
